Nephrotic syndrome adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 6,723 adverse event reports that record the MedDRA preferred term Nephrotic syndrome. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 410 reports in the 12 months to June 2026 and 437 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,090 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 410 (under 0.1%) record this term. Reports for female patients were 38.8% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 85 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Nephrotic syndrome name as a suspect product, in order of name
Drug	Class	Reports with this term
Amlodipine	Calcium channel blocker	55
Amoxicillin	Penicillin-class antibacterial	25
Atezolizumab	Programmed death Receptor-1 blocking antibody	29
Atorvastatin		36
Avastin	Vascular endothelial growth factor inhibitor	230
Azathioprine	Purine antimetabolite	40
Belimumab	B lymphocyte stimulator-specific inhibitor	26
Benlysta	B lymphocyte stimulator-specific inhibitor	25
Bevacizumab	Vascular endothelial growth factor inhibitor	159
Cabometyx	Kinase inhibitor	63
Capecitabine	Nucleoside metabolic inhibitor	33
Carboplatin	Platinum-based drug	74
CellCept	Antimetabolite immunosuppressant	56
Ciclosporin		74
Corticotropin		36
Crestor	HMG-CoA reductase inhibitor	25
Cyclophosphamide	Alkylating drug	169
Cyclosporine	Calcineurin inhibitor immunosuppressant	187
Cyramza	Vascular endothelial growth factor receptor 2 antagonist	55
Cytarabine	Nucleoside metabolic inhibitor	27
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	37
Dasatinib	Kinase inhibitor	27
Dexamethasone	Corticosteroid	75
Diclofenac	Nonsteroidal anti-inflammatory drug	83
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	54
Enbrel	Tumor necrosis factor blocker	74
Esomeprazole	Proton pump inhibitor	28
Etoposide	Topoisomerase inhibitor	25
Everolimus	Kinase inhibitor	26
Fluorouracil	Nucleoside metabolic inhibitor	63
Folic acid		29
Furosemide	Loop diuretic	72
Gemcitabine hydrochloride	Nucleoside metabolic inhibitor	27
Gemzar		31
Humira		109
Ibuprofen	Nonsteroidal anti-inflammatory drug	105
Imatinib	Kinase inhibitor	25
Inlyta	Kinase inhibitor	32
Irinotecan		30
Keytruda	Programmed death Receptor-1 blocking antibody	69
Lansoprazole	Proton pump inhibitor	34
Lenvatinib	Kinase inhibitor	34
Lenvima	Kinase inhibitor	94
Methotrexate	Folate analog metabolic inhibitor	125
Methylprednisolone	Corticosteroid	142
Mycophenolate mofetil	Antimetabolite immunosuppressant	337
Mycophenolic acid	Antimetabolite immunosuppressant	29
Naproxen	Nonsteroidal anti-inflammatory drug	39
Neoral	Calcineurin inhibitor immunosuppressant	91
Nexavar	Kinase inhibitor	34
Nexium	Proton pump inhibitor	68
Nexium 24HR	Proton pump inhibitor	50
Nivolumab	Programmed death Receptor-1 blocking antibody	65
Omeprazole	Proton pump inhibitor	100
Opdivo	Programmed death Receptor-1 blocking antibody	81
Oxaliplatin	Platinum-based drug	60
Paclitaxel	Microtubule inhibitor	62
Pantoprazole	Proton pump inhibitor	114
Pantoprazole sodium	Proton pump inhibitor	50
Pegasys	Interferon alpha	36
Pembrolizumab	Programmed death Receptor-1 blocking antibody	38
Prednisolone	Corticosteroid	254
Prednisone	Corticosteroid	295
Prevacid	Proton pump inhibitor	123
Prevacid 24 HR	Proton pump inhibitor	59
Prilosec	Proton pump inhibitor	69
Prilosec OTC	Proton pump inhibitor	35
Prograf	Calcineurin inhibitor immunosuppressant	80
Ramipril	Angiotensin converting enzyme inhibitor	48
Ramucirumab	Vascular endothelial growth factor receptor 2 antagonist	26
Rapamune		29
Rebif	Interferon beta	34
Remicade	Tumor necrosis factor blocker	46
Revlimid	Thalidomide analog	29
Ribavirin	Nucleoside analog antiviral	48
Rituximab	CD20-directed cytolytic antibody	260
Soliris	Complement inhibitor	30
Sutent	Kinase inhibitor	57
Tacrolimus	Calcineurin inhibitor immunosuppressant	272
Tecentriq	Programmed death Receptor-1 blocking antibody	56
Truxima	CD20-directed cytolytic antibody	29
Velcade	Proteasome inhibitor	27
Votrient	Kinase inhibitor	56
Xeloda	Nucleoside metabolic inhibitor	28
Yervoy	CTLA-4-directed blocking antibody	30

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 43 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Nephrotic syndrome name, in order of name
Class	Reports with this term
Alkylating drug	224
Aminosalicylate	33
Angiotensin 2 receptor blocker	110
Angiotensin converting enzyme inhibitor	86
Anti-epileptic agent	25
Antimalarial	52
Antimetabolite immunosuppressant	438
B lymphocyte stimulator-specific inhibitor	51
beta-Adrenergic blocker	33
Calcineurin inhibitor immunosuppressant	644
Calcium channel blocker	67
CD20-directed cytolytic antibody	348
CD38-directed cytolytic antibody	30
Complement inhibitor	40
Corticosteroid	792
CTLA-4-directed blocking antibody	55
Cytochrome P450 3A inhibitor	25
Folate analog metabolic inhibitor	157
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	27
Herpes simplex virus nucleoside analog DNA polymerase inhibitor	29
HMG-CoA reductase inhibitor	78
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	42
Interferon alpha	38
Interferon beta	47
Kinase inhibitor	703
Loop diuretic	80
Microtubule inhibitor	77
Mood stabilizer	43
Nonsteroidal anti-inflammatory drug	369
Nucleoside analog antiviral	50
Nucleoside metabolic inhibitor	240
Penicillin-class antibacterial	33
Platinum-based drug	136
Programmed death Receptor-1 blocking antibody	341
Proteasome inhibitor	57
Proton pump inhibitor	763
Purine antimetabolite	50
Sodium-Glucose cotransporter 2 inhibitor	50
Thalidomide analog	47
Topoisomerase inhibitor	38
Tumor necrosis factor blocker	170
Vascular endothelial growth factor inhibitor	422
Vascular endothelial growth factor receptor 2 antagonist	81

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Nephrotic syndrome, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Nephrotic syndrome
Age	Reports	Share
Under 2	60	0.9%
2 to 11	377	5.6%
12 to 17	247	3.7%
18 to 44	981	14.6%
45 to 64	1,535	22.8%
65 to 74	949	14.1%
75 and over	668	9.9%
Age not given	1,906	28.4%

Sex of the patient in the reports that record Nephrotic syndrome
Sex	Reports	Share
Female	2,608	38.8%
Male	3,258	48.5%
Unknown or not given	857	12.7%

Age and sex are as the report gives them. 19.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Nephrotic syndrome: adverse event reports that record this term. https://reportedreactions.com/reaction/nephrotic-syndrome/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Nephrotic syndrome mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page